Enzalutamide and Leuprolide Acetate in Non-Metastatic Hormone-Sensitive Prostate Cancer: The Sooner the Better?

Future OncologyVol. 20, No. 4 EditorialEnzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?Emilio Francesco Giunta, Lorenzo Gasperoni & Ugo De GiorgiEmilio Francesco Giunta https://orcid.org/0000-0002-5383-4469Department of Medical Oncology, Meldola, Italy, Lorenzo GasperoniOncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy & Ugo De Giorgi *Author for correspondence: Tel.: +39 0543 739 100; https://orcid.org/0000-0001-7520-2908Department of Medical Oncology, Meldola, ItalyPublished Online:7 Feb 2024https://doi.org/10.2217/fon-2023-1019AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: androgen deprivation therapycastrationenzalutamidepatient-reported outcomesprostate cancersafetyReferences1. Van den Broeck T, van den Bergh RCN, Briers E et al. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur. Urol. Focus 6(2), 231–234 (2020).MedlineGoogle Scholar2. Freedland SJ, De Giorgi U, Gleave M et al. A Phase III randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 11(8), e046588 (2021).MedlineGoogle Scholar3. Freedland SJ, de Almeida Luz M, De Giorgi U et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N. Engl. J. Med. 389(16), 1453–1465 (2023).Medline CASGoogle Scholar4. https://www.drugs.com/history/xtandi.html (accessed on 5th November 2023).Google Scholar5. Scher HI, Fizazi K, Saad F et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).Medline CASGoogle Scholar6. Payne H, Robinson A, Rappe B et al. European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. Int. J. Cancer 150(5), 837–846 (2022).Medline CASGoogle Scholar7. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).Medline CASGoogle Scholar8. Sternberg CN, Fizazi K, Saad F et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 382(23), 2197–2206 (2020).Medline CASGoogle Scholar9. Freedland SJ, Gleave M, De Giorgi U et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid. 2(12), (2023). Epub ahead of print 21 October 2023 doi: 10.1056/EVIDoa2300251MedlineGoogle Scholar10. De Giorgi U, Freedland SJ, Gleave ME et al. Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints. Ann. Oncol. 34, S960–S961 (2023).MedlineGoogle Scholar11. Freedland SJ, Gleave ME, De Giorgi U et al. Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK. Ann. Oncol. 34, S961 (2023).Google Scholar12. Andriole GL. The impact of prostate cancer and hormonal therapy on bone. Rev. Urol. 11(4), 185–189 (2009).MedlineGoogle Scholar13. Mottet N, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESURSIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 79(2), 243–262 (2021).Medline CASGoogle Scholar14. Caroli P, Sandler I, Matteucci F et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur. J. Nucl. Med. Mol. Imaging 45(12), 2035–2044 (2018).Medline CASGoogle Scholar15. Linder S, van der Poel HG, Bergman AM et al. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocr. Relat. Cancer 26(1), R31–R52 (2018).MedlineGoogle Scholar16. Salvi S, Casadio V, Conteduca V et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget 7(25), 37839–37845 (2016).MedlineGoogle Scholar17. Conteduca V, Jayaram A, Romero-Laorden N et al. Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer. Eur. Urol. 75(3), 368–373 (2019).Medline CASGoogle Scholar18. De Giorgi U, Sansovini M, Severi S et al. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. Br. J. Cancer 125(9), 1226–1232 (2021).MedlineGoogle Scholar19. de Jong AC, Danyi A, van Riet J et al. Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nat. Commun. 14(1), 1968 (2023).Medline CASGoogle Scholar20. Grypari IM, Tzelepi V, Gyftopoulos K. DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology. Int. J. Mol. Sci. 24(14), 11418 (2023).Medline CASGoogle ScholarFiguresReferencesRelatedDetails Vol. 20, No. 4 STAY CONNECTED Metrics Downloaded 65 times History Received 14 April 2023 Accepted 22 January 2024 Published online 7 February 2024 Published in print February 2024 Information© 2024 Expert Publishing Medicine Ltd trading as Taylor & FrancisKeywordsandrogen deprivation therapycastrationenzalutamidepatient-reported outcomesprostate cancersafetyFinancial disclosureThe authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download